Use access key #2 to skip to page content.
$9.29 0.05 (0.54%)
7/24/2008 10:02 AM

CV Therapeutics, Inc. (CVTX)

CAPS Rating:
****

A biopharmaceutical company focused on the discovery, development and commercialization of new small molecule drugs for the treatment of cardiovascular diseases.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating CVTX

Add Stock to Watchlist

What the Community Thinks

Total Members

248 Outperforms
30 Underperforms
 

All-Stars

80 Outperforms
9 Underperforms
 

Wall Street

3 Outperforms
2 Underperforms
 

Members bullish on CVTX are also bullish on:

Members bearish on CVTX are also bearish on:

Ticker Tags

Small Cap (1922), Micro Cap (4824), Optionable (32), Biotechnology (294), Founder CEO (24)
Suggest a tag

CV Therapeutics, Inc. At A Glance

Current Price: $9.29
Last Trade Time: 7/24/2008 10:02 AM
Open: $9.28
Previous Close: $9.24
Daily Range: $9.24 - $9.50
52-Week Range: $5.41 - $12.41
Volume: 38,035
Market Cap: $561.13M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

CVTX VS S&P 500 (SPY)

CVTX 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for CVTX

More Headlines...

Top Bull Pitch

Recs

3

CV Therapeutics, Inc. (CVTX)

Avatar Sayder (82.13) Submitted: 3/19/08 11:25 PM

Current FDA approval for Regadenoson should be coming within a few months, as well as the improved rating approval for Ranexa later around the July-October time frame. Additionally, institutional ownership is greater than 100% of total shares outstanding (several people are currently shorting the st...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

4

CV Therapeutics, Inc. (CVTX)

Avatar NetscribeBiotech (79.01) Submitted: 1/08/07 7:50 AM

CV Therapeutics is a development-stage company specializing in small-molecule drugs to treat chronic cardiovascular diseases. The firm's only marketed product Ranexa, licensed from a Roche subsidiary, treats chronic angina for select patients by altering metabolism.

The company witnessed a phenomen...More

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 50 :   1 2 3 4 5 Next » Jump to page:

Recs

0

 (CVTX)

Avatar Elisaiah (51.66) Submitted: 7/17/08 8:54 PM : Outperform Start Price: $8.54 CVTX Score: 7.90

Management finally getting it together; costs in line with revenue and drug pipeline looks promising. Maybe a takeover target....

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CVTX)

Avatar pharmacist2011 (< 20) Submitted: 6/25/08 6:40 PM : Outperform Start Price: $8.63 CVTX Score: 10.12

biotech's - recession proof also, plus great pipeline

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CVTX)

Avatar costanostra (40.91) Submitted: 5/06/08 5:17 PM : Outperform Start Price: $9.13 CVTX Score: 10.04

They make a drug to treat Angina, basically it's a heart condition that can be caused by high stress. I actually invested in this stock several years ago in the high single digits for a nice gain. I'm sure they have made more progress on marketing Ranexa since then.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (CVTX)

Avatar johnnymack91362 (97.72) Submitted: 4/27/08 7:17 PM : Outperform Start Price: $9.07 CVTX Score: 11.36

europe approvals and nice royalty situation, still are'nt being valued.

Report this Post Replies: 0 | Reply | Permalink

Recs

3

 (CVTX)

Avatar Sayder (82.13) Submitted: 3/19/08 11:25 PM : Outperform Start Price: $5.88 CVTX Score: 61.91

Current FDA approval for Regadenoson should be coming within a few months, as well as the improved rating approval for Ranexa later around the July-October time frame. Additionally, institutional ownership is greater than 100% of total shares outstanding (several people are currently shorting the stock). Just one piece of good news could send this stock up if the institutions hold onto their shares. With a shortage of shares on the market, the share price should really move as the others try to cover their shorts. However, without FDA approval of their drugs (and soon), they probably won't survive 2 more years.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 50 :   1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 5 of 5  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackJimCramer 81.36 06/15/07 06/15/07 Outperform 3W $11.37-17.94%-16.41%-1.53
TrackFirstAlbany 75.99 04/25/07 04/25/07 Outperform NS $8.71+7.12%-13.97%+21.09
TrackCitigroup 86.71 03/28/07 03/28/07 Underperform NS $7.47+24.90%-9.98%-34.88
TrackDeutscheSec 87.31 03/26/07 03/26/07 Underperform NS $7.67+21.67%-10.84%-32.51
TrackCantorFitz 87.29 01/19/07 01/19/07 Outperform NS $14.38-35.12%-10.24%-24.88

Results 1 - 5 of 5  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners